LY-293284: Difference between revisions
CSV import |
CSV import |
||
| Line 23: | Line 23: | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
{{pharma-stub}} | {{pharma-stub}} | ||
{{No image}} | |||
Revision as of 23:41, 10 February 2025
LY-293284 is a serotonin receptor agonist that was developed by Eli Lilly and Company. It is a potent and selective 5-HT1A receptor agonist, which has been used in scientific research to investigate the role of the 5-HT1A receptor in various processes.
History
LY-293284 was first synthesized by researchers at Eli Lilly and Company, a pharmaceutical company based in the United States. The compound was developed as part of the company's ongoing efforts to develop new treatments for neurological disorders and psychiatric disorders.
Pharmacology
LY-293284 is a potent and selective agonist for the 5-HT1A receptor, a type of serotonin receptor. Serotonin is a neurotransmitter that plays a key role in many different physiological processes, including mood regulation, appetite, sleep, and cognition. By activating the 5-HT1A receptor, LY-293284 can influence these processes.
Research
Research on LY-293284 has primarily focused on its potential use in the treatment of psychiatric disorders. In preclinical studies, the compound has been shown to have anxiolytic effects, suggesting that it could potentially be used to treat anxiety disorders. However, further research is needed to fully understand the therapeutic potential of LY-293284.
